Indication: Diffuse Large B-cell Lymphoma
Title: DLBCL/SADAL: A Phase 2b Open-label Study of selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Drug: selinexor

SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Rights

Drug: selinexor

PreclinicalPhase IPhase IIPhase III
Preclinical
Phase I
Phase II
Phase III